Lu-PSMA treatment seems to be well tolerated and safe. One common treatment-related grade 1 adverse event is dry mouth in up to 87% of men after radioligand therapy (RLT). Therefore, in the vast majority no treatment is needed. Hematologic toxicity such as thrombocytopenia caused serious ...
177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer BACKGROUND: Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherap...
Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes 来自 Springer 喜欢 0 阅读量: 22 作者: H Nguyen,K Hird,J Cardaci,S Smith,NP Lenzo 展开 摘要: Whilst prostate cancer is the fourth most common cancer ...
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 ...
FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic prostate cancer has a 5-year survival rate of less than 30%3; mCRPC patients who progress on multiple lines of therapy have limited trea...
225-actinium-PSMA/docetaxel/lutetium-177-PSMA-imaging-and-therapy. Reactions Weekly 1882, 14 (2021). https://doi.org/10.1007/s40278-021-05481-4 Download citation Published20 November 2021 Issue DateNovember 2021 DOIhttps://doi.org/10.1007/s40278-021-05481-4 Access this article Log in via an...
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017 Mar;64(1):52-60.Emmett L, et al. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of...
Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer in Germany: population-based data with multicenter validation from 2016 to 2020doi:10.1055/s-0043-1766222Flegar, L.Thoduka, S.Librizzi, D.Luster, M.Zacharis, A....
Lutetium-177 PSMA radioligand therapy of metastatic castration- resistant prostate cancer: Safety and efficacy. J Nucl Med... HR Kulkarni,A Singh,K Niepsch,... - Society of Nuclear Medicine & Molecular Imaging-meeting 被引量: 3发表: 2016年 [ 177 Lu]-PSMA-617 radionuclide therapy in ...
The median68Ga-PSMA PET tumor/liver SUVmeanratio was 0.94 (range 0.33-2.62). The median tumor-absorbed dose was 0.47 (range, 0.01-4.66) Gy. Highest median doses by tumor site were 1.84 (range, 0.76-2.92) Gy in local recurrences and 1.35 (range, 0.33-2.62) Gy in bone lesions. ...